Global Human Normal Immunoglobulin 麻豆原创 Research Report 2024

Publication ID:

PB506245263

Publication Date:

June 20, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Human normal immunoglobulin is a highly purified protein extracted from human plasma. It contains immunoglobulin G (IgG), which is a type of antibody that has been used as a medicine since the 1980s and has a wide range of activity against organisms that can cause infection. The normal range of IgG varies depending on age, with the IgG normal range for age 0-1 years being between 231-1411 mg/dL and the IgG normal range for age 10-11 years being between 698-1560 mg/dL.
The global Human Normal Immunoglobulin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Human Normal Immunoglobulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Normal Immunoglobulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Human Normal Immunoglobulin include CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG and Hualan Bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Normal Immunoglobulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Normal Immunoglobulin.
Report Scope
The Human Normal Immunoglobulin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Normal Immunoglobulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Normal Immunoglobulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Others
Segment by Application
Government Institutions
Private Sector
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Normal Immunoglobulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Normal Immunoglobulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Human Normal Immunoglobulin 麻豆原创 Overview
1.1 Product Overview and Scope of Human Normal Immunoglobulin
1.2 Human Normal Immunoglobulin Segment by Type
1.2.1 Global Human Normal Immunoglobulin 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Others
1.3 Human Normal Immunoglobulin Segment by Application
1.3.1 Global Human Normal Immunoglobulin 麻豆原创 Value by Application: (2024-2030)
1.3.2 Government Institutions
1.3.3 Private Sector
1.3.4 Other
1.4 Global Human Normal Immunoglobulin 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Human Normal Immunoglobulin Revenue 2019-2030
1.4.2 Global Human Normal Immunoglobulin Sales 2019-2030
1.4.3 Global Human Normal Immunoglobulin 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Normal Immunoglobulin 麻豆原创 Competition by Manufacturers
2.1 Global Human Normal Immunoglobulin Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Human Normal Immunoglobulin Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Human Normal Immunoglobulin Average Price by Manufacturers (2019-2024)
2.4 Global Human Normal Immunoglobulin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Normal Immunoglobulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Normal Immunoglobulin, Product Type & Application
2.7 Human Normal Immunoglobulin 麻豆原创 Competitive Situation and Trends
2.7.1 Human Normal Immunoglobulin 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Normal Immunoglobulin Players 麻豆原创 Share by Revenue
2.7.3 Global Human Normal Immunoglobulin 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Normal Immunoglobulin Retrospective 麻豆原创 Scenario by Region
3.1 Global Human Normal Immunoglobulin 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Normal Immunoglobulin Global Human Normal Immunoglobulin Sales by Region: 2019-2030
3.2.1 Global Human Normal Immunoglobulin Sales by Region: 2019-2024
3.2.2 Global Human Normal Immunoglobulin Sales by Region: 2025-2030
3.3 Global Human Normal Immunoglobulin Global Human Normal Immunoglobulin Revenue by Region: 2019-2030
3.3.1 Global Human Normal Immunoglobulin Revenue by Region: 2019-2024
3.3.2 Global Human Normal Immunoglobulin Revenue by Region: 2025-2030
3.4 North America Human Normal Immunoglobulin 麻豆原创 Facts & Figures by Country
3.4.1 North America Human Normal Immunoglobulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Normal Immunoglobulin Sales by Country (2019-2030)
3.4.3 North America Human Normal Immunoglobulin Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Normal Immunoglobulin 麻豆原创 Facts & Figures by Country
3.5.1 Europe Human Normal Immunoglobulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Normal Immunoglobulin Sales by Country (2019-2030)
3.5.3 Europe Human Normal Immunoglobulin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Normal Immunoglobulin 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Human Normal Immunoglobulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Normal Immunoglobulin Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Normal Immunoglobulin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Normal Immunoglobulin 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Human Normal Immunoglobulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Normal Immunoglobulin Sales by Country (2019-2030)
3.7.3 Latin America Human Normal Immunoglobulin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Normal Immunoglobulin 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Human Normal Immunoglobulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Normal Immunoglobulin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Normal Immunoglobulin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Normal Immunoglobulin Sales by Type (2019-2030)
4.1.1 Global Human Normal Immunoglobulin Sales by Type (2019-2024)
4.1.2 Global Human Normal Immunoglobulin Sales by Type (2025-2030)
4.1.3 Global Human Normal Immunoglobulin Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Human Normal Immunoglobulin Revenue by Type (2019-2030)
4.2.1 Global Human Normal Immunoglobulin Revenue by Type (2019-2024)
4.2.2 Global Human Normal Immunoglobulin Revenue by Type (2025-2030)
4.2.3 Global Human Normal Immunoglobulin Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Human Normal Immunoglobulin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Normal Immunoglobulin Sales by Application (2019-2030)
5.1.1 Global Human Normal Immunoglobulin Sales by Application (2019-2024)
5.1.2 Global Human Normal Immunoglobulin Sales by Application (2025-2030)
5.1.3 Global Human Normal Immunoglobulin Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Human Normal Immunoglobulin Revenue by Application (2019-2030)
5.2.1 Global Human Normal Immunoglobulin Revenue by Application (2019-2024)
5.2.2 Global Human Normal Immunoglobulin Revenue by Application (2025-2030)
5.2.3 Global Human Normal Immunoglobulin Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Human Normal Immunoglobulin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Corporation Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CSL Behring Human Normal Immunoglobulin Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Corporation Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Grifols Human Normal Immunoglobulin Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Biotest
6.3.1 Biotest Corporation Information
6.3.2 Biotest Description and Business Overview
6.3.3 Biotest Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biotest Human Normal Immunoglobulin Product Portfolio
6.3.5 Biotest Recent Developments/Updates
6.4 Kedrion
6.4.1 Kedrion Corporation Information
6.4.2 Kedrion Description and Business Overview
6.4.3 Kedrion Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kedrion Human Normal Immunoglobulin Product Portfolio
6.4.5 Kedrion Recent Developments/Updates
6.5 CBPO
6.5.1 CBPO Corporation Information
6.5.2 CBPO Description and Business Overview
6.5.3 CBPO Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 CBPO Human Normal Immunoglobulin Product Portfolio
6.5.5 CBPO Recent Developments/Updates
6.6 Emergent (Cangene)
6.6.1 Emergent (Cangene) Corporation Information
6.6.2 Emergent (Cangene) Description and Business Overview
6.6.3 Emergent (Cangene) Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Emergent (Cangene) Human Normal Immunoglobulin Product Portfolio
6.6.5 Emergent (Cangene) Recent Developments/Updates
6.7 Kamada
6.6.1 Kamada Corporation Information
6.6.2 Kamada Description and Business Overview
6.6.3 Kamada Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kamada Human Normal Immunoglobulin Product Portfolio
6.7.5 Kamada Recent Developments/Updates
6.8 CNBG
6.8.1 CNBG Corporation Information
6.8.2 CNBG Description and Business Overview
6.8.3 CNBG Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.8.4 CNBG Human Normal Immunoglobulin Product Portfolio
6.8.5 CNBG Recent Developments/Updates
6.9 Hualan Bio
6.9.1 Hualan Bio Corporation Information
6.9.2 Hualan Bio Description and Business Overview
6.9.3 Hualan Bio Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Hualan Bio Human Normal Immunoglobulin Product Portfolio
6.9.5 Hualan Bio Recent Developments/Updates
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Corporation Information
6.10.2 Shanghai RAAS Description and Business Overview
6.10.3 Shanghai RAAS Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shanghai RAAS Human Normal Immunoglobulin Product Portfolio
6.10.5 Shanghai RAAS Recent Developments/Updates
6.11 Sichuan Yuanda Shuyang
6.11.1 Sichuan Yuanda Shuyang Corporation Information
6.11.2 Sichuan Yuanda Shuyang Human Normal Immunoglobulin Description and Business Overview
6.11.3 Sichuan Yuanda Shuyang Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sichuan Yuanda Shuyang Human Normal Immunoglobulin Product Portfolio
6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.12 ADMA Biologics
6.12.1 ADMA Biologics Corporation Information
6.12.2 ADMA Biologics Human Normal Immunoglobulin Description and Business Overview
6.12.3 ADMA Biologics Human Normal Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.12.4 ADMA Biologics Human Normal Immunoglobulin Product Portfolio
6.12.5 ADMA Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Normal Immunoglobulin Industry Chain Analysis
7.2 Human Normal Immunoglobulin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Normal Immunoglobulin Production Mode & Process
7.4 Human Normal Immunoglobulin Sales and 麻豆原创ing
7.4.1 Human Normal Immunoglobulin Sales Channels
7.4.2 Human Normal Immunoglobulin Distributors
7.5 Human Normal Immunoglobulin Customers
8 Human Normal Immunoglobulin 麻豆原创 Dynamics
8.1 Human Normal Immunoglobulin Industry Trends
8.2 Human Normal Immunoglobulin 麻豆原创 Drivers
8.3 Human Normal Immunoglobulin 麻豆原创 Challenges
8.4 Human Normal Immunoglobulin 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.